No abstract

In this study the effects of oral administration of bifenthrin (BF) on biochemical and histological parameters of male rat's liver have been evaluated. Dose response was evaluated on different groups of rats with respect to different time interval of 2, 8 and 31 days. Divided the animals in four groups as A, B, C and D. Group B, C and D received bifenthrin concentration (60 mg/ kg per body weight), (70 mg/kg body per weight) and (85 mg/kg per body weight), respectively. Group A is as control and each and every animal in this group received equal volume of mustard oil without BF. Finding being observed in the rats treated group with bifenthrin showed dose dependent signs and severity of acute/sub-acute poisoning meticulously that is they were more severe as the dose concentration was increased. Collection of the blood sample and the serums were used for analyses of lipid profile, proteins (serum albumin, serum globulins and serum total proteins/STP, serum albumin) and different liver enzymes. It was observed that a higher concentration of bifenthrin raised level of cholesterol in all the treated groups while the HDL level decreases and the Level of LDL in treated group was higher as compared to normal rats. The higher levels of AST and ALT in the treated rats were observed as compared to the normal group in relation to time and doses employed. Moreover, a high concentration of BF doses shows decreasing trend of the concentration of total serum protein, serum albumin and globulins decreased. In addition it has observed that bile duct hyperplasia along with degenerative changes in hepatocytes by histopathological examination of liver and there was dose dependent severity. Our data reports the toxic actions of bifenthrin at different doses administered during the study which produced biochemical alterations in serum profile and moderate histological lesions in liver.

The increase incidence of obesity, stress and aging in genetically predisposed population has lead to an increase in the incidence of type 2 diabetes mellitus. This led to the development of new drugs such as thiazolidinediones (TZDs) which is a agonist of Peroxisome Proliferator-Activated Receptor (PPARgamma).Pioglitazone is a TZD have recently been identified for its severe cardiovasculara complication. Pioglitazone is oral hypoglycemic agent which has been shown to be effective by lowering insulin resistance.Due to its cardiovasculaqr risk factor it is combined with adjunct vitamin E,an antioxidant in the present study. The safety and efficacy of pioglitazone are increased several fold along with vitamin E.

No abstract